• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

4

CATEGORIES

  • 13
  • 2
  • 1
  • 1
  • 1

PRICE

0
0
0
17

PUBLISHED

0
0
1
17

PRODUCT TYPE

17

Search "Alzheimer's Disease – The Evaluation & Management of Dementia 2013" returned 17 results.

PRODUCT TITLE
Neuroprotection - Drugs, Markets and Companies Neuroprotection - Drugs, Markets and Companies - Product Thumbnail Image

Neuroprotection - Drugs, Markets and Companies

This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many...

June 2015
FROM

Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Namenda (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Namenda (Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Razadyne/Reminyl (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Razadyne/Reminyl (Alzheimer’s Disease) -...

September 2013
FROM

Aricept (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Aricept (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Aricept (Alzheimer’s Disease) - Forecast and Market...

September 2013
FROM

Namenda XR (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Namenda XR (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Namenda XR (Alzheimer’s Disease) - Forecast and...

July 2013
FROM

Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Exelon (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Exelon (Alzheimer’s Disease) - Forecast and Market...

September 2013
FROM

TRx0237 (Alzheimer's Disease) - Forecast and Market Analysis to 2022

TRx0237 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “TRx0237 (Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

Arimenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Arimenda (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Arimenda (Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

MK-8931(Alzheimer's Disease) - Forecast and Market Analysis to 2022

MK-8931(Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “MK-8931(Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

EVP-6124 (Alzheimer's Disease) - Forecast and Market Analysis to 2022

EVP-6124 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “EVP-6124 (Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

Lu AE58054 (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Lu AE58054 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lu AE58054 (Alzheimer’s Disease) - Forecast and...

July 2013
FROM

Solanezumab (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Solanezumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Solanezumab (Alzheimer’s Disease) - Forecast and...

July 2013
FROM

Gantenerumab (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Gantenerumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Gantenerumab (Alzheimer’s Disease) - Forecast...

July 2013
FROM

Crenezumab (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Crenezumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Crenezumab (Alzheimer’s Disease) - Forecast and...

July 2013
FROM

Biomarkers: Discovery Techniques and Applications - A Global Market Overview

The potential offered by biomarkers in shaping the outcomes of clinical trials, identifying new drug targets and developing diagnostic assays for detecting diseases early is immense, which has ensued...

November 2013
FROM

Positron Emission Tomography (PET) Markets

The medical imaging segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the computer and digital information technology segment Continuous...

July 2011
FROM

Global Transdermal Drug Delivery Market to 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and Swot Investigation

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 320 tables...

February 2015
FROM
Loading Indicator

Our Clients

Symantec Corporation Sonoco Products Company Tiffany & Co. ITT Corporation Exxon Mobil Corp. Samsonite International S.A. Kellogg's Co.